The subscription period for Stayble’s new issue in connection to the intended listing on Nasdaq First North Growth Market begins today and the Company invites to investment events

February 2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Today on February 4, 2020, the subscription period to subscribe for units in the intended initial public offering from Stayble Therapeutics AB (“Stayble” or the “Company”) commences and continues until February 18, 2020.  The Company invites potential investors to attend investment meetings at Stayble in Gothenburg February 11, Mangold in Malmö february 12 and Mangold in Stockholm February 13.

Today is the first day of the subscription period for participating in Stayble’s forthcoming new issue prior to the intended listing on Nasdaq First North Growth Market. As announced on January 31, 2020, a prospectus regarding the offer to subscribe for units in the Company has been published. The Prospectus and the subscription form can be found on Stayble’s website, www.staybletherapeutics.com and on Mangold’s website, www.mangold.se.

Investor meetings

Investor meeting, February 11, 2020, 12 PM in Gothenburg
Investor meeting, February 12, 2020, 12 PM in Malmö
Investor meeting February 13, 2020, 12 PM in Stockholm

For more information, please visit www.staybletherapeutics.com/upcoming-events/.

Advisors

Mangold Fondkommission AB are financial advisors and Advokatfirman Schjødt are legal advisors in the Offering
 

Subscription

Subscriptions of Units shall be made through;

  • Electronic subscription using Bank-ID on Mangold’s website www.mangold.se.
  • Subscription form available on Stayble’s website, www.staybletherapeutics.com and Mangold’s website www.mangold.se.
  • Customers of Nordnet Bank AB (”Nordnet” can subscribe for the Offering directly on Nordnet’s website, www.nordnet.se. Further information can be obtained on www.nordnet.se.
  • Customers of Avanza Bank AB (”Avanza”) can subscribe for the Offering directly on Avanza’s website, www.avanza.se. Further information can be obtained on www.avanza.se.
     

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397